ReviewMedical devices (Auckland, N.Z.)2026
Efficacy, Safety and Oncological Outcomes of Minimally Invasive Approaches (EMR, ESD and TAMIS) for Early Rectal Tumors: A Systematic Review and Meta-Analysis.
Review in Medical devices (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Device-based minimally invasive techniques have transformed the management of early rectal tumors by enabling organ-preserving treatment while reducing morbidity compared with radical surgery. Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are flexible endoscopic techniques, whereas transanal minimally invasive surgery (TAMIS) is a transanal access platform that allows excision using laparoscopic or robotic instrumentation. These approaches differ in access route, instrumentation, and depth of tissue excision. However, comparative evaluation from a device-centered and oncological perspective remains limited. Methods: A systematic review and proportional meta-analysis were conducted in accordance with PRISMA guidelines. PubMed, MEDLINE, Embase, Ovid, Scopus, and Web of Science were searched for studies reporting outcomes of EMR, ESD, or TAMIS in adult patients with early rectal tumors. Primary outcomes included R0 resection rate, en bloc resection rate, and local and distant recurrence. Secondary outcomes included procedure time, bleeding, and reintervention rates. Random-effects models were applied, and heterogeneity was assessed using the I Results: A total of 108 studies encompassing 8705 patients were included. EMR demonstrated the shortest procedure time, ESD showed the lowest local and distant recurrence rates, and TAMIS achieved the highest en bloc resection rates. Despite differences in technical performance, R0 resection rates were broadly comparable across platforms. Substantial heterogeneity was observed, reflecting variation in tumor characteristics, access platforms, instrumentation, and operator expertise. Conclusion: EMR, ESD, and TAMIS are safe and effective device-based minimally invasive platforms for the treatment of early rectal tumors. Despite differences in access route and technological configuration, oncological outcomes appear more strongly influenced by tumor biology, depth, and pathological assessment than by the choice of platform alone. These findings support device-informed decision-making by guiding platform selection according to lesion characteristics and oncological outcomes while highlighting the need for randomized trials to optimize device selection in early rectal cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.